Clinical Trial Search

Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…

Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants

Primary: Overall Response (OR) — 0; 3; 3; 1 Participants

Primary: Overall Response Rate — 11 Participants

Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001

Primary: Time to Tumor Progression — 334; 176 days

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg

Primary: Stiffness of Thyroid Nodules as Measured by Elastography — 2.7; 3.8; 2.7 meters/second

Primary: Tumor Response Rate to LBH589. — 13; 0 participants

Primary: Number of Participants With Overall Response (OR) — 0 Participants

Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants

Primary: Increased Radioiodine Uptake — 6 Participants

Primary: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 9; 7 Participants — p=<0.10

Primary: Progression-Free Survival (PFS) — 10.0; 5.7 months — p=0.080

Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants

Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…

Primary: Objective Response Rate (ORR) — 50.0; 35.6 Percentage of participants

Primary: Overall Survival Rate — 0 percentage of participants alive

Primary: Progression Free Survival — 241 days

Primary: Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1 — 10 Participants

Primary: Percentage of Participants With Objective Response (OR) — 34.6 percentage of participants

Primary: To Determine the Efficacy (Best Response) of BAY 43-9006 (Objective Response Rate and Stable Disease) in Patients With Metastatic Thyroid Carcinoma. — 0; 16; 22; 1…

Primary: Objective Response Rate — 6 Participants

Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants

Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants

Primary: Shear-Wave Elastography (SWE) Values in kiloPascals (kPa) — 17.50; 31.03; 23.64; 32.14 kPa

Primary: Change in Tumor Size — 4.7 cm

Primary: Median Progression Free Survival — 12.5 months

Primary: Overall Response Rate (in Cohorts 1-3) — 49; 14; 0 percentage of participants